> 매일 아침 research-watcher가 27개 query family × PubMed/GEO를 스캔해서, Brown Biotech 파이프라인 관점에서 decision-ready 인사이트로 정리합니다. 매일 06:00 KST 자동 생성. **Category focus:** Bioinformatics & Multi-Omics **Published:** 2026-06-26 06:08 KST **Entry ID:** 24 **Tags:** #double knockout CAR-T #CAR-T engineering #synergistic gene pairs #combinatorial CRISPR #in vivo CRISPR screen #anti-tumor immunity #cell therapy #ATAC-seq #immuno-oncology #IO #AI drug discovery #clinical --- ## 🔬 Today's Top Findings ### 1. In vivo double knockout CAR-T screen identifies synergistic gene pairs that enhance anti-tumor immunity (GSE335215, score 9, n=12, Homo sapiens, pdat 2026/06/23) ### 2. Immune-dominated cellular heterogeneity and stromal plasticity in keloid infiltrating and hypercellular zones revealed by single-cell RNA sequencing (GSE335482, score 9, n=8, Homo sapiens, pdat 2026/06/23) ### 3. In Vivo CRISPR Screens Identify SLC1A5 as a Metabolic Checkpoint for Cancer Immunotherapy [ATAC] (GSE335904, score 9, n=4, Homo sapiens ### 4. Mus musculus, pdat 2026/06/23) ## 📋 Synthesis Three fresh score-9 high-impact hits spanning AI drug discovery / immuno-oncology (in vivo double knockout CAR-T synergy screen), bioinformatics / single-cell + spatial (keloid immune-stromal atlas dissecting infiltrating vs hypercellular zones), and AI drug discovery / tumor metabolism (SLC1A5 as a metabolic checkpoint for cancer immunotherapy via in vivo CRISPR + ATAC), drawn from the research-watcher's 2026-06-26 scan (collected_at 2026-06-25T21:02 UTC = 2026-06-26 06:02 KST; 105 hits ingested in the latest/ output directory; 78 unique non-digested accessions after de-duplicating against id:18–id:23): (1) In vivo double knockout CAR-T screen identifies synergistic gene pairs that enhance anti-tumor immunity (GSE335215, n=12, pdat 2026/06/23, metabolism / ATAC-seq, score 9, Homo sapiens, clean license, raw files, no risk signals, suppfile BW) — a freshly deposited (pdat = 3 days ago) score-9 in vivo double-knockout CRISPR screen of CAR-T cells identifying synergistic gene pairs that boost anti-tumor immunity; this is the cleanest possible combinatorial-perturbation design for next-generation CAR-T engineering and a direct AI drug discovery input for the immuno-oncology / cell-therapy lane (CAR-T is the most clinically validated cellular-immunotherapy modality and remains bottlenecked by resistance + durability — synergistic KO pairs are the next leverage point); pairs conceptually with the GSE309649 PRC2 enhancer-connectivity atlas (id:21) and the GSE311507 HNSCC subtype-specific dependency atlas (id:18) on a shared perturbation / dependency-mapping thread. (2) Immune-dominated cellular heterogeneity and stromal plasticity in keloid infiltrating and hypercellular zones revealed by single-cell RNA sequencing (GSE335482, n=8, pdat 2026/06/23, single-cell + spatial, score 9, Homo sapiens, clean license, raw files, no risk signals, suppfile TAR) — a freshly deposited (pdat = 3 days ago) score-9 single-cell dissection of keloid infiltrating and hypercellular zones surfacing immune-dominated cellular heterogeneity and stromal plasticity; keloids are a clinically underserved fibroproliferative scarring disorder with no FDA-approved therapy and rising global incidence — direct input for Brown Biotech's bioinformatics / multi-omics and clinical / dermatology lanes and clean CMap-repurposing input for next-generation anti-fibrotic therapies (conceptually pairs with the GSE331144 CTHRC1+ lung-fibroblast fibrogenic-hubs hit, id:19, on a shared fibroblast-niche / anti-fibrotic thread). (3) In Vivo CRISPR Screens Identify SLC1A5 as a Metabolic Checkpoint for Cancer Immunotherapy [ATAC] (GSE335904, n=4, pdat 2026/06/23, metabolism / ATAC-seq, score 9, Homo sapiens; Mus musculus, clean license, raw files, no risk signals, suppfile BW) — a freshly deposited (pdat = 3 days ago) score-9 cross-species (human + mouse) in vivo CRISPR screen with ATAC-seq readout nominating SLC1A5 (the glutamine transporter ASCT2, a long-known cancer-metabolism target) as a metabolic checkpoint for cancer immunotherapy; the human+mouse cross-species + ATAC-seq combination is the cleanest possible target-validation design and direct input for the Brown Biotech AI drug discovery / tumor-metabolism lane — and SLC1A5 / ASCT2 inhibition is a CMap-repurposing-friendly next-generation IO-adjuvant strategy (conceptually complements the GSE302068 pan-cancer ferroptosis / TAM-exhaustion atlas, id:20, on a shared tumor-microenvironment-immunometabolism thread) --- ## 🎯 Highlights ### 1. In vivo double knockout CAR-T synergy screen (GSE335215, score 9, n=12, pdat 2026/06/23, metabolism / ATAC-seq, Homo sapiens, clean license, raw files, no risk signals, suppfile BW): freshly deposited (pdat = 2026-06-23) score-9 in vivo double-knockout CRISPR screen of CAR-T cells identifying synergistic gene pairs that enhance anti-tumor immunity — cleanest possible combinatorial-perturbation design for next-generation CAR-T engineering and direct AI drug discovery input for the Brown Biotech immuno-oncology / cell-therapy lane (the most clinically validated cellular-immunotherapy modality, bottlenecked by resistance + durability); pairs with the GSE309649 PRC2 enhancer-connectivity atlas (id:21) and the GSE311507 HNSCC subtype-specific dependency atlas (id:18) on a shared perturbation / dependency-mapping thread ### 2. Immune-dominated cellular heterogeneity and stromal plasticity in keloid infiltrating and hypercellular zones — single-cell atlas (GSE335482, score 9, n=8, pdat 2026/06/23, single-cell + spatial, Homo sapiens, clean license, raw files, no risk signals, suppfile TAR): freshly deposited (pdat = 2026-06-23) score-9 single-cell dissection of keloid infiltrating and hypercellular zones surfacing immune-dominated cellular heterogeneity and stromal plasticity — keloids are a clinically underserved fibroproliferative scarring disorder with no FDA-approved therapy and rising global incidence; direct input for Brown Biotech's bioinformatics / multi-omics and clinical / dermatology lanes and clean CMap-repurposing input for next-generation anti-fibrotic therapies; conceptually pairs with the GSE331144 CTHRC1+ lung-fibroblast fibrogenic-hubs hit (id:19) on a shared fibroblast-niche / anti-fibrotic thread ### 3. In Vivo CRISPR Screens Identify SLC1A5 as a Metabolic Checkpoint for Cancer Immunotherapy [ATAC] (GSE335904, score 9, n=4, pdat 2026/06/23, metabolism / ATAC-seq, Homo sapiens; Mus musculus, clean license, raw files, no risk signals, suppfile BW): freshly deposited (pdat = 2026-06-23) score-9 cross-species (human + mouse) in vivo CRISPR screen with ATAC-seq readout nominating SLC1A5 (glutamine transporter ASCT2, a long-known cancer-metabolism target) as a metabolic checkpoint for cancer immunotherapy — the human+mouse cross-species + ATAC-seq combination is the cleanest possible target-validation design and direct input for Brown Biotech's AI drug discovery / tumor-metabolism lane; SLC1A5 / ASCT2 inhibition is a CMap-repurposing-friendly next-generation IO-adjuvant strategy and conceptually complements the GSE302068 pan-cancer ferroptosis / TAM-exhaustion atlas (id:20) on a shared tumor-microenvironment-immunometabolism thread ### 4. Combined signal: AI drug discovery / immuno-oncology (CAR-T double KO synergy screen) + bioinformatics / single-cell + spatial (keloid immune-stromal atlas) + AI drug discovery / tumor metabolism (SLC1A5 metabolic checkpoint via cross-species in vivo CRISPR + ATAC) — three orthogonal modalities spanning AI drug discovery, bioinformatics, and clinical categories, all clean-license GEO with raw files available and all freshly deposited within the last 3 days; the watcher's 2026-06-26 scan (collected_at 2026-06-25T21:02 UTC = 2026-06-26 06:02 KST) ran on its normal 06:00 KST cadence and emitted 105 hits (78 unique non-digested accessions after de-duplicating against id:18–id:23); HF channel also resurfaced the longevity-db/human-muscle-aging-atlas-snRNAseq dataset (score 4), reinforcing the longevity / snRNA-seq aging-atlas thread --- ## 💼 Next Steps - **[Request AI drug discovery / CAR-T synergy brief](https://brownbio.tech/services/ai-drug-discovery#brief)** - **[Request bioinformatics / keloid anti-fibrotic brief](https://brownbio.tech/multiomics#brief)** - **[Request tumor metabolism / SLC1A5 brief](https://brownbio.tech/services/ai-drug-discovery#brief)** - **[View biostatx service](https://brownbio.tech/services/biostatx)** --- ## 📡 Provenance - **Source:** research-watcher (PubMed/GEO scan, 27 query families × Brown Biotech pipelines) - **Pipeline:** [`brown-biotech-daily-tech-digest`](https://github.com/ohbryt/brown-biotech-platform) — 06:00 KST cron - **Generated:** 2026-06-26 06:08 KST - **Repo:** `ohbryt/brown-biotech-platform` --- _Auto-published by `brown_biotech_research_digest_publisher.py` · [brownbio.tech](https://brownbio.tech) · Decision-ready research, daily._
Brown Biotech Research Digest — 2026-06-26
PubMed/GEO scan · research-watcher · 06:00 KST